Entries by Max

177Lu-M3-12: a Novel PSMA-Targeted Radioligand Shows Higher Tumour Uptake Than 177Lu-PSMA-617 in Preclinical Study

A new preclinical study published in EJNMMI Research reports promising results for 177Lu-M3-12, an experimental PSMA-targeted radioligand designed to improve tumour targeting and potentially reduce radiation exposure to healthy tissues in prostate cancer. The treatment uses lutetium-177, the same radioactive isotope employed in 177Lu-PSMA-617 (Pluvicto), but incorporates a different molecular structure featuring a hydrophilic linker. […]

Two Experimental Prostate Cancer Treatments Discontinued: AZD9750 and AZD8359

Two experimental prostate cancer drug development programs have been discontinued, according to an October 30, 2026, pipeline update. The decision affects AZD9750, an androgen receptor (AR) degrader, and AZD8359, a STEAP2-targeted T-cell engager, both of which were undergoing early clinical investigation in metastatic prostate cancer. AZD9750 was an oral AR degrader designed to eliminate the […]

ADCT-241: PSMA-Targeted Antibody–Drug Conjugate Shows Bystander Activity in Prostate Cancer Models

A new preclinical study published in Molecular Cancer Therapeutics reports encouraging results for ADCT-241, an experimental antibody–drug conjugate (ADC) designed to target prostate-specific membrane antigen (PSMA) in prostate cancer. ADCT-241 combines a PSMA-targeting antibody with a cytotoxic payload derived from exatecan, a topoisomerase I inhibitor. Unlike PSMA-targeted radioligand therapies, which deliver radiation to tumour cells, […]

Metabolic Blood Profiles May Predict Survival and Treatment Response in Advanced Prostate Cancer

A new analysis from the randomized phase II SAKK 08/14 trial suggests that metabolic markers circulating in the blood may help predict survival and treatment response in patients with metastatic castration-resistant prostate cancer (mCRPC). However, the analysis found no reliable metabolic signature identifying patients who benefit from adding metformin to enzalutamide. The study investigated metabolomics, […]

Phase 1 Trial: ROR1-Targeting ADC HDM2005 Shows Early Antitumor Activity in Heavily Pretreated Prostate Cancer

Early results presented at ESMO 2026 suggest that HDM2005, an experimental antibody-drug conjugate (ADC) targeting ROR1, may have antitumor activity in patients with metastatic castration-resistant prostate cancer (mCRPC) who have exhausted several established treatment options. HDM2005 is designed to recognize ROR1, a protein expressed by certain cancer cells, and deliver the chemotherapy agent monomethyl auristatin […]

ProBio Trial: Niraparib Plus Abiraterone Shows Greater Clinical Benefit in BRCA-Mutated mCRPC

New findings from the randomized phase 3  ProBio platform trial suggest that niraparib combined with abiraterone and prednisone may extend clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) carrying homologous recombination repair (HRR) gene alterations, particularly BRCA1/2 mutations. However, no overall survival advantage was demonstrated. The analysis included 99 patients, with 54 receiving […]

Rinzimetostat May Limit Prostate Cancer Lineage Plasticity and Restore Therapeutic Targets

New preclinical and translational findings presented at ESMO 2026 suggest that rinzimetostat (ORIC-944), an experimental epigenetic therapy, may help prevent prostate cancer cells from changing their identity to escape androgen receptor (AR)-targeted treatments. Rinzimetostat inhibits the PRC2 complex through its EED subunit. PRC2 regulates gene expression and contributes to lineage plasticity, a process through which […]

Newsletter 43/2026

  LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! New findings from the ESMO 2026 meeting are starting to come in, and there’s plenty to talk about. So grab yourself something to drink, get comfortable, and enjoy! Stay strong and fight on! As usual, we […]

Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer

The phase 3 DASL-HiCaP trial, presented at ESMO 2026, has demonstrated improved metastasis-free survival with the addition of darolutamide to androgen deprivation therapy (ADT) and radiotherapy in patients with localised or locally advanced prostate cancer at high risk of recurrence. The randomised, placebo-controlled study enrolled 1,106 patients, who received darolutamide or placebo alongside ADT and […]

UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide

New results from a randomised substudy of the phase 3 PROTEUS trial, presented at ESMO 2026, show that adding apalutamide and androgen deprivation therapy (ADT) before and after radical prostatectomy improves outcomes compared with surgery alone in patients with high-risk localised or locally advanced prostate cancer. The substudy enrolled 408 patients, including 102 receiving perioperative […]